Communiqués Chimerix, Inc.

Actions

CMRX

US16934W1062

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/04/2025			Varia. 5j.	Varia. 1 janv.
8,540 ^USD	-.--%		-.--%	-

21/04/25	Jazz Pharmaceuticals finalise l'acquisition de Chimerix pour 935 millions de dollars	MT
21/04/25	Jazz Pharmaceuticals plc (NasdaqGS : JAZZ) a finalisé l'acquisition de Chimerix, Inc. (NasdaqGM : CMRX).	CI

Communiqués

24/03/25	Chimerix Reports Fourth Quarter and Year End 2024 Financial Results	AQ
21/03/25	Chimerix: Q4 Earnings Snapshot	AQ
21/03/25	Chimerix Reports Fourth Quarter and Year End 2024 Financial Results	AQ
11/03/25	CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX	BU
10/03/25	Chimerix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
07/03/25	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
05/03/25	Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio	PR
18/02/25	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
18/02/25	Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma	AQ
29/01/25	Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium	AQ
27/01/25	Chimerix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
24/01/25	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
13/01/25	Chimerix to Speak Today at The White House Cancer Moonshot Forum	AQ
30/12/24	Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma	AQ
09/12/24	Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End	AQ
06/12/24	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
11/11/24	Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting	AQ
07/11/24	Chimerix: Q3 Earnings Snapshot	AQ
07/11/24	Chimerix : Reports Third Quarter 2024 Financial Results and Provides Operational Update Form 8 K	PU
07/11/24	Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update	AQ
04/11/24	Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024	AQ
01/11/24	Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024	AQ
21/10/24	Chimerix Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	AQ
18/10/24	Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
03/09/24	Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference	AQ